[Porphyria cutanea tarda following treatment with depot estrogens in patients with prostate cancer].
In 3 out of 133 patients suffering from prostatic cancer and treated with depot estrogens a porphyria cutanea tarda was found after a follow-up ranging from few months to 10 years. Therefore, a defect of the uroporphyrinogen decarboxylase has been postulated. The therapy could be continued under small doses of chlorochin diphosphate.
Linss
G
G
Hautklinik des Bezirkskrankenhauses Frankfurt.
Schmechel
C
C
D000368:Aged; D003692:Delayed-Action Preparations; D045166:Estradiol Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011164:Porphyrias / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012871:Skin Diseases / Q000139:chemically induced*
D003692:Delayed-Action Preparations; D045166:Estradiol Congeners
Porphyria cutanea tarda nach Behandlung mit Depot-Ostrogenen bei Patienten mit Prostatakarzinom.